AVTE צמיחה צפויה ברווח למניה לשנה הבאה Aerovate Therapeutics, Inc

Aerovate Therapeutics (AVTE) is developing an inhaled imatinib to combat pulmonary hypertension, utilizing a unique dry powder drug delivery technology. An assessment of the forward EPS trend demonstrates a stabilization of market expectations, while -20.90 indicates the level of this metric. The absence of current sales is offset by a significant cash reserve dedicated to the development of new R&D projects.
פילוחי מדדים פיננסיים ומדדי שוק עבור Aerovate Therapeutics, Inc. (AVTE)

This indicator reflects the consolidated earnings per share (EPS) growth forecast for the coming year, calculated as the difference between expected and current EPS values. By analyzing the target net income per share growth rate, investors assess the capitalization potential of Aerovate Therapeutics (AVTE), whose valuation depends on the commercial success of its innovative inhalation drug delivery system for the treatment of pulmonary hypertension.